Search Technologies
Displaying 11 - 20 of 33 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Compounds for Treating Parasitic Infections
Published Monday, May 15, 2023Summary Researchers at the University of Maryland, Baltimore and the University of Maryland, College Park have synthesized a new class of 1,3-thiazolidine-2,4-dione derivatives that exhibit potent activity against several protozoan parasites,...
Investigator(s): Fengtian Xue, Iqbal Hamza
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): Parsitology, infection, Immunology
Docket: FX-2015-021
-
Novel Ketamine Metabolites for Treating Depression, Anxiety & Addiction
Published Monday, November 7, 2022UMB inventors from Prof. Todd Gould’s lab, along with their collaborators, made the pivotal discovery in 2016 that certain stable ketamine metabolites exerted antidepressant actions via a different mechanism (independent of NMDAR inhibition), which made these compounds excellent drug candidates, without the negative side effects associated with...
Investigator(s): Todd Gould, Jaclyn Highland, Panos Zanos, Craig Thomas, Patrick Morris
Categories: Therapeutics, Small molecules
Keyword(s): small molecule; ketamine-related; depression; addiction
Docket: TG-2021-015
-
Targeting Protein Translation with Novel Small Molecules for Treating Pancreatic and Prostate Cancer
Published Sunday, June 2, 2019Medicinal chemists at UMB designed a family of novel small molecules which block key drivers of the protein translational complex by degrading MNK1/2 (i.e., mitogen-activated protein kinase (MAPK)-interacting kinase 1/2), thus inhibiting the activation of the eIF4E axis and inhibiting tumor growth. Lead...
Investigator(s): Vincent Njar, Puranik Purushottamachar, Andrew Kwegyir-Afful, Francis Murigi
Categories: Therapeutics, Small molecules
Keyword(s): oncology, Small molecule therapeutic
Docket: VN-2013-094
-
Analogs of GHB Lacking GABAergic Activity
Published Monday, February 11, 2019The present invention relates to esthers of 3-hydroxyphenyacetic acid and their use to treat narcolepsy and other sleep disorders. Gamma-hydroxybutyric acid (GHB) is a known agonist for the GHB receptor. Unfortunately it also acts at GABA receptors directly and through its metabolization into alpha aminobutyric acid (GABA). As a result,...
Investigator(s): Andrew Coop, Maharaj Ticku, Charles France
Categories: Therapeutics, Small molecules
Keyword(s): narcolepsy, cataplexy, sleep disorderes
Docket: AC-2006-050
-
Small Molecule Lipid II Inhibitors
Published Friday, February 16, 2018Drug resistance in microorganisms is an urgent and growing concern as more and more microorganisms are found with resistance to commonly used treatments. For bacterial infections alone, approximately 2 million people are infected a year and 23,000 deaths can be directly correlated to drug-resistant bacteria (CDC). There is an urgent need for...
Investigator(s): Eric DeLeeuw, Jamal Chauhan, Steven Fletcher, Alexander MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): Anti-infective
Docket: ED-2016-042
-
Small molecule inhibitors of the Mcl-1 oncoprotein based on a 1-hydroxy-2-naphthoate scaffold
Published Monday, January 29, 2018Myeloid cell leukemia-1 (Mcl-1) is an oncoprotein over-expressed in multiple human cancers and is responsible for resistance to conventional anti-cancer agents. An anti-apoptotic member of the Bcl-2 protein family, Mcl-1 plays a major role in the homeostasis of cell proliferation and cell death. The cell-killing function of the pro-apoptotic...
Investigator(s): Steven Fletcher, Maryanna Lanning, Lijia Chen
Categories: Therapeutics, Small molecules
Keyword(s): oncology
Docket: SF-2014-103
-
New Compounds to Treat Metastatic and Triple Negative Breast Cancer
Published Wednesday, May 31, 2017Despite multi-modal treatment, approximately 40% of all women with breast cancer will suffer a recurrence. While the 10-year overall survival rate for women without recurrence is 84%, this drops to 49%-72% for women with a locoregional recurrence or a second primary malignancy. Luminal breast cancer has the highest rates of relapse, often...
Investigator(s): Antonino Passaniti, Alexander MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): breast cancer, oncolytic, small molecule, CADD
Docket: AP-2015-080
-
Treatment of depression, anhedonia, chronic stress conditions and PTSD with (2R6R)-HNK
Published Thursday, November 10, 2016Ketamine exerts rapid and sustained antidepressant effects after a single dose in patients with depression, but its use is associated with undesirable side effects. With the novel discovery of the actions of ketamine metabolites on the AMPA and not the NMDA glutamate receptors as previously reported,...
Investigator(s): Todd Gould, Panos Zanos, Irving Wainer, Carl Zarate, Craig Thomas, Patrick Morris, Ruin Moaddel
Categories: Therapeutics, Small molecules
Keyword(s): Therapeutic, depression, CNS
Docket: TG-2015-116, TG-2016-107
-
Use of Micro-RNA Mimics as Therapeutic Agents for Inhibition of Neuronal Apoptosis Following Traumatic Brain Injury.
Published Tuesday, August 25, 2015Reduced blood flow to the brain due to thrombosis, embolism, cardiac arrest, or injury, can result in focal or global cerebral ischemia. Ischemia leads to alterations in brain metabolism, reduction in metabolic rates, and subsequent neuronal death. Ischemia can have irreversible sequela. Post-injury treatment to curtail cell death due to acute...
Investigator(s): Alan Faden, Bogdan Stoica, Boris Sabirzhanov
Categories: Therapeutics, Small molecules, Biologics
Keyword(s): Traumatic Brain Injury, micro RNA, miRNA mimics, ischemia
Docket: AF-2014-011
-
Tight junction permeation enhancer peptides
Published Monday, March 23, 2015Human zonulin or pre-haptoglobin 2 (HP2) is known to reversibly regulate intestinal permeability by modulating intercellular tight junctions. Itactivates protease-activated receptor (PAR) 2, and induces signaling...
Investigator(s): Alessio Fasano, Stefanie N. Vogel
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Small molecules, Biologics, Methods of Treatment
Keyword(s): peptides, zot, zonulin, crohns asthma, glioma, celiac disease, type I diabetes, tight junction
Docket: AF-2004-004